Examining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals
William Borden
Advertisement
Articles by William Borden
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How CMS’ Final Negotiation Rule Treats New Drug Formulations
2
Big Three Distributors Lean on Specialty for Profit Growth
3
Bob Cochran: Direct-to-Patient Was a 'Watershed Moment' for Commercial Trade
4
The AI Efficiency Trap: Why Faster Tasks Alone Won’t Transform Life Sciences
5